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Mortality in HIV infection is independently predicted by host iron status
and SLC11A1 and HP genotypes, with new evidence of a gene-nutrient
interaction1–3
Joann M McDermid, Maarten F Schim van der Loeff, Assan Jaye, Branwen J Hennig, Chris Bates, Jim Todd, Giorgio Sirugo,
Adrian V Hill, Hilton C Whittle, and Andrew M Prentice
ABSTRACT
Background: Iron-related genes and iron status may independently
contribute to variable HIV outcomes. The nature of the biologically
plausible gene-nutrient interaction remains unknown.
Objectives: The objectives were to investigate whether iron-related
genotypes and clinically abnormal iron status independently predict
mortality in HIV and whether a gene-nutrient interaction exists.
Design: Baseline plasma, DNA, and clinical data were obtained
from 1362 HIV-seropositive Gambian adults followed for 11.5 y
to ascertain all-cause mortality. Iron status was estimated on the
basis of plasma iron, soluble transferrin receptor (sTfR), ferritin,
transferrin, transferrin index, and log(sTfR/ferritin). One haptoglobin
(HP) and 5 SLC11A1 (NRAMP1) polymorphisms were genotyped.
Results: SLC11A1-SLC3 and CAAA polymorphisms were the best
independent genetic predictors of mortality [adjusted mortality rate
ratio (95% CI)]: SLC3:G/C = 0.59 (95% CI: 0.45, 0.85), CAAA:del/
ins = 1.51 (95% CI: 1.10, 2.07). In an adjusted model that included
all polymorphisms, SLC1:199/199, SLC1:other/other, SLC6a:A/A,
and CAAA:del/ins were associated with significantly greater mor-
tality, whereas Hp 2–1 and SLC3:G/C were protective. In unad-
justed analyses, all biomarker concentrations were significantly
associated with mortality. Extending previous findings, both low
and elevated iron states were associated with mortality, but the
nature of the risk was variable, with linear, inversely linear, and
U-shaped associations depending on the biomarker. Mortality was
significantly lower in HIV-2 than in HIV-1 infection in the presence
of abnormal (low or elevated) iron status. A gene-iron interaction
was detected (likelihood-ratio test P = 0.018); however, subject
numbers restricted category-specific interpretation.
Conclusions: Iron-related genes, iron status, and their interaction
predict mortality in HIV. These findings illustrate the complexity
and uncertainty surrounding best practice for managing abnormal
iron status and anemia during HIV infection and in regions with
a high risk of infection. Am J Clin Nutr 2009;90:1–9.
INTRODUCTION
Time-to-disease progression and mortality varies considerably
in HIV infection. Fully understanding factors explaining this
variation assists in guiding clinical decisions and informing
public health policy, while also providing a theoretical basis for
the development of novel therapies or justifying existing treatments.
Anemia is associated with the progression and mortality in
HIV infection (1–3), but the hemoglobin concentration alone
does not reflect the overall or tissue iron exposure. Dramatic iron
redistribution occurs during all types of infection as a result of the
acute phase response (APR), and iron status can be interpreted as
low or elevated depending on which biomarker is chosen (4).
Whereas hemoglobin is an important routine clinical marker, it is
possible that another biomarker, one indicative of elevated iron
status, is a more biologically relevant predictor of HIVoutcomes.
Indeed, elevated iron status has been associated with increased
mortality by our group (5) and others (6) and with increased viral
load (7) and potentially increased viral virulence, predisposition
to opportunistic infections, and altered immune responses and
immunodeficiency (8). Collectively, the evidence that iron meta-
bolism and homeostasis play a role in the outcome of HIV in-
fection is strong, with practical implications in the clinical
interpretation and management of iron status and anemia pre-
ceding and during infection.
Iron status in HIV infection has thus far been reported in the
absence of consideration for potential background genetic ef-
fects. Phenotypic analysis of haptoglobin (Hp), encoded by the
haptoglobin (HP) gene, has been related to survival time and/or
viral loads in HIV infection (7, 9). It has also been associated
1 From the Division of Nutritional Sciences, Cornell University, Ithaca,
NY (JMM); the Medical Research Council International Nutrition Group,
Nutrition and Public Health Intervention Research Unit, Department of Ep-
idemiology & Population Health, London School of Hygiene & Tropical
Medicine, London, United Kingdom (JMM, BJH, and AMP); Medical Re-
search Council Laboratories, Fajara, The Gambia (MFSvdL, AJ, GS, and
HCW); the Tropical Epidemiology Group, Infectious Disease Epidemiology
Unit, Department of Epidemiology & Population Health, London School of
Hygiene & Tropical Medicine, London, United Kingdom (JT); Ospedale San
Pietro FBF, Rome, Italy (GS); the Wellcome Trust Centre for Human Ge-
netics, University of Oxford, Oxford, United Kingdom (BJH and AVH); and
the Micronutrient Status Research Section, Medical Research Council Hu-
man Nutrition Research, Cambridge, United Kingdom (CB).
2 Supported by the Bristol Myers Squibb Mead Johnson Unrestricted
Grant Programme, the Canadian Institutes for Health Research, Canadian
Women’s Club Centennial Scholarship Fund, the Gordon Smith Travel
Scholarship, the Medical Research Council (United Kingdom), and the
Overseas Research Student Awards Scheme and the Wellcome Trust.
3 Address reprint requests and correspondence to JM McDermid, Division
of Nutritional Sciences, Cornell University, 310 Savage Hall, Ithaca, NY
14853. E-mail: jmm585@cornell.edu.
Received March 4, 2009. Accepted for publication April 25, 2009.
doi: 10.3945/ajcn.2009.27709.
Am J Clin Nutr 2009;90:1–9. Printed in USA.  2009 American Society for Nutrition 1
 AJCN. First published ahead of print May 27, 2009 as doi: 10.3945/ajcn.2009.27709.
Copyright (C) 2009 by the American Society for Nutrition 
with differential susceptibility, prognosis, or recurrence of the
highly prevalent opportunistic infection, tuberculosis (TB) (8,
10). The mechanisms may include functional phenotypic dif-
ferences in relation to free-hemoglobin binding or iron accumu-
lation that influences the degree of iron-driven oxidative stress or
alters the immune response. Because Mycobacterium tubercu-
losis resides within the phagolysomes of macrophages, any
changes in iron status at this level could have significant im-
plications for the host-pathogen iron balance. Solute carrier
family 11 member 1 [SLC11A1, or natural resistance-associated
macrophage protein-1 (NRAMP1)] is hypothesized to encode
a protein acting as a macrophage-level iron gatekeeper. Evidence
from diverse populations, albeit predominantly HIV-seronegative
subjects, repeatedly shows that SLC11A1 polymorphisms are as-
sociated with susceptibility to TB (11). Similarly to reports in the
iron-status literature, genetic studies have not considered the ef-
fect of host iron status on these observations.
In the present study, mortality in HIV infection was in-
vestigated as a function of the independent effects of 6 poly-
morphisms from 2 iron-related genes. Findings from an earlier
report were extended by examining the iron-status and mortality
association across the total spectrum of iron states, from low to
elevated iron status, and additionally, findings were examined in
relation to HIV type. Uniquely, we investigated whether a bi-
ologically plausible gene-nutrient interaction was detectable.
SUBJECTS AND METHODS
Study design and population
This study used existing clinical data and archived biological
samples that were collected for the Medical Research Council
(MRC) Laboratories HIV-seroprevalent Clinical Cohort based
in The Gambia, West Africa (12). Subjects recruited between
1 January 1991 and 31 December 2001 were eligible if aged
18 y and if peripheral blood mononuclear cells/buffy coats and
baseline (defined as 90 d after the first HIV-seropositive di-
agnosis) plasma were available. The MRC/Gambian government
ethics committee approved the cohort establishment and bio-
logical sample collection, and subsequently, in conjunction with
the London School of Hygiene & Tropical Medicine ethics com-
mittee, the clinical chemistry and genotyping specific to this
study. During the time data were originally collected and ar-
chived, viral load testing and antiretroviral therapy were not
routinely available in The Gambia.
Mortality ascertainment
The main outcome was all-cause mortality. Follow-up con-
tinued at the clinic and/or at home visits throughout the country
until 1 June 2002. Subjects were considered lost-to-follow-up if
mortality status could not be ascertained during these scheduled
visits, and these subjects were censored on the last date on which
they were known with certainty to be alive.
Genotyping
HP genotyping was performed by using an allele-specific
polymerase chain reaction (PCR)–based method distinguishing
the major allelic variants (Hp1 and Hp2) of the a-chain (13).
SLC11A1 polymorphisms SLC1 [promoter microsatellite:5#(CA)n;
rs34448891] and CAAA (CAAA deletion/insertion:276del4;
rs17229009) were genotyped by fluorescent polyacrylamide gel
electrophoresis of amplicons visualized on the ABI 3700 cap-
illary electrophoresis device (Perkin Elmer-ABI, Foster City, CA).
SLC3 (an intron 4 single nucleotide transversion:469+14G/C;
rs3731865), SLC6a (a nonconservative aspartate-to-asparagine
change in the carboxy terminal end:D543N; rs17235409), and
SLC6b (TGTG insertion/deletion:1729+55del4; rs17235416) were
genotyped by using the MassARRAY Homogenous MassEXTEND
assay (hME Sequenom, Cambridge, United Kingdom). Internal
control samples were included during genotyping to assess pos-
sible discrepancies in genotype calls.
Iron-status analyses
Details of baseline iron-status estimation in this cohort were
described elsewhere (5). In brief, soluble transferrin receptor
(sTfR) (R&D Systems, Abingdon, United Kingdom) and ferritin
(Immuno-biological Laboratories, Hamburg, Germany) were mea-
sured by enzyme-linked immunosorbent assay. Plasma iron was
assessed by using an endpoint assay (ABXDiagnostics, Shefford,
United Kingdom) and transferrin by turbidimetry (ABX Diag-
nostics, Shefford, United Kingdom). Composite indexes were cal-
culated as follows: transferrin index = iron (lmol/L)/transferrin
(g/L) and TfR:F = log(sTfR/ferritin). Hemoglobin concentrations
were measured during routine clinical screening. Iron status was
determined at cohort entry, and the effects of subsequent in-
terventions with iron-repletion therapy for anemia were not
quantified.
Acute phase response analysis
a1-Antichymotrypsin (ACT) as an indication of the degree of
APR was measured by using a nephelometric assay (DakoCy-
tomation Inc, Ely, United Kingdom).
Statistical analyses
Survival analyses were conducted by using Poisson multi-
plicative regression models with Intercooled Stata 9.2 (Stata-
Corp, College Station, TX). Our null hypothesis was that there
were no differences in the probability of mortality across iron-
status or genotype categories. This was tested against an alter-
native hypothesis that there were differences in mortality in
categories other than the baseline or reference category. Deciding
whether to model a covariate as a continuous or categorical
variable often involves a tradeoff between the best-fitting model
in statistical terms and a model that is readily interpretable and
acceptable by clinicians or patients. In this study, justification of
covariate categorization was based on evidence, where available,
of clinically relevant cutoffs that are used to define normal or
abnormal iron status or commonly used cutoffs in the HIV lit-
erature (ie, CD4 cell counts) or developing countries [ie, body
mass index (BMI; in kg/m2)]. Well-defined cutoffs for each iron-
status biomarker by race, sex, age, or under different clinical
circumstances are not universally accepted or used between
studies. Where possible, we used values that have been reported
in the literature from studies that most closely resembled our
population. Potential confounders of the iron status (plasma
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iron, ferritin, transferrin, sTfR, transferrin index, and TfR:F) and
mortality relation included baseline age (categorized in 4 age
groups: 18–25, 26–35, 36–45, and .45 y), sex, BMI (2 cate-
gories: 18 and ,18, based on reference 14), natural log-
transformed ACT concentration, absolute CD4 cell count
(grouped in 3 categories: .500, 200–500, and ,200 cells/lL),
HIV type [HIV-1, HIV-2, and both HIV-1 and HIV22 (HIV-
dual) infection], and hemoglobin concentration. These variables,
in addition to self-reported ethnicity (5 categories: Mandinka,
Jola, Wolof, Fula, and “otherwise”), were included in the ad-
justed genetic analyses.
Main genetic effects
The gene-mortality relation was analyzed in 3 ways: the
genotypes of each polymorphism were analyzed in separate
unadjusted models, in separate adjusted-models, and in a single
adjusted-model combining polymorphisms from both genes.
Main iron effects
The relation between iron status and mortality was assessed in
3 ways: by analyzing the raw data using biomarker concen-
trations or index values; by clinically classifying biomarkers
according to low, normal, or elevated iron status (15–19)
(Table 1); and by stratifying on HIV type.
Joint interaction effect
Based on a priori knowledge, elevated iron status was con-
sidered to be associated with greater mortality. According to the
cutoffs established from the literature in Table 1, iron status was
dichotomized into elevated iron status (= 1) or otherwise (= 0).
Individual iron risks were then added, giving an overall iron-risk
score of low = 0–1, medium = 2–3, and high  4. A priori
knowledge of the probability of mortality associated with each
of the genotypes was unavailable. Consequently, an ad hoc
classification of the combined genotype risk was created based
on the outcome of the independent effect of genotypes on
mortality in this study (Table 2, analysis C). High-risk geno-
types were coded as Hp:1–1, 2–2; SLC1:199/other, other/other;
SLC3:G/G; SLC6a:A/A; SLC6b:ins/del; CAAA:del/ins, ins/ins =
1; and otherwise = 0. Scores were added, giving an overall genetic-
risk score of low = 0–1; medium = 2–3; high 4. Regression
coefficients and SEs were used to calculate the predicted rate
ratios and 95% CIs. The presence of a significant interaction was
tested for using the likelihood-ratio test on unadjusted Poisson
regression models.
RESULTS
Characteristics of this cohort were described elsewhere (5, 12).
In brief, of the 1362 participants, sex was approximately equally
distributed (52.7% women), and the mean (6SD) age was 35 6
10 y. At cohort entry, the median absolute CD4 count for the
cohort was 234 [interquartile range (IQR): 83, 469 cells/lL],
and HIV-1 (67.3%) was the predominant viral type identified
(HIV-2 = 31.3%, HIV-dual = 1.5%). The mean (6SD) hemo-
globin concentration (100 6 23 g/L) and median ACT con-
centration (0.44; IQR: 0.33, 0.68 g/L) suggest that many were
experiencing an APR at the time of blood sampling. The mean
(6SD) BMI was significantly lower (P, 0.001) in men (18.56
3.3) than in women (20.2 6 4.6), as was the median (IQR)
absolute CD4 cell count [men: 160 cells/lL (55, 349 cells/lL);
women: 317 cells/lL (133, 579 cells/lL); P , 0.001], which
may have reflected a tendency toward a longer duration be-
tween HIV-seroconversion and HIV diagnosis among men in
this cohort.
Mortality
Follow-up continued up to 11.5 y [2714 person-years (PY)],
with 713 deaths observed. The proportion of subjects lost to
follow-up was 21.6% (median follow-up time: 0.81 y; IQR: 0.15,
2.31 y), with a tendency for these subjects to be female, younger,
and healthier at baseline.
Iron-related genes and mortality
We selected 5 SLC11A1 polymorphisms distributed along the
entire SLC11A1 genomic sequence and one HP polymorphism
for genetic analysis. The genotype distribution is summarized in
Table 2. The most frequently observed genotypes in this cohort
were Hp 2–1, SLC1:199/199, SLC3:G/G, SLC6a:G/G, SLC6b:
ins/ins, and CAAA:del/ins. The genotypes for all polymorphisms
were in Hardy-Weinberg Equilibrium (HWE), with the excep-
tion of CAAA (P = 0.025). When examined separately by eth-
nicity according to mortality outcome, all were in HWE with the
exception of the CAAA polymorphism among subjects who were
alive at cohort exit (P = 0.012).
The SLC3:G/C genotype was consistently associated with
a significantly lower probability of mortality than was the pre-
dominant homozygous genotype SLC3:G/G in all genetic
models (analyses A-C) (Table 2). After adjustment for multiple
confounders (analyses B-C), CAAA:del/ins was also associated
with significantly greater mortality than was the CAAA:del/del
genotype. When all polymorphisms of both genes were included
in an adjusted model (analysis C), the genetic associations be-
came stronger and the SLC1:199/other, SLC1:other/other, and
SLC6a:A/A genotypes were also associated with significantly
TABLE 1
Clinical classification of biomarkers of iron status1
Biomarker concentration Elevated status Normal status Low status
sTfR (nmol/L) ,10.6 10.6–29.9 .29.9
Iron (lmol/L) .30.0 8.6–30.0 ,8.6
Transferrin (g/L) ,2.0 2.0–3.6 .3.6
Transferrin index (lmol/g) .5.9 5.0–5.9 ,5.0
TfR:F ,21.45 21.45–0.40 .0.40
Ferritin (lg/L)
Age 44 y
Men .200 12–200 ,12
Women .150 12–150 ,12
Age .44 y
Men .300 12–300 ,12
Women .200 12–200 ,12
1 Hemoglobin was defined according to degree of anemia where 100
g/L was defined as normal, 80 to ,100 g/L as anemia, and ,80 g/L as
severe anemia (20, 21). sTfR, soluble transferrin receptor; TfR:F, log(soluble
transferrin receptor:ferritin).
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increased mortality. Conversely, SLC3:G/C and Hp 2–1 were
associated with significantly lower mortality.
Iron status and mortality
Iron-status biomarkers and associated indexes were important
predictors of mortality in HIV infection (Table 3), with all results
statistically significant in unadjusted analyses. After adjustment
for multiple confounders, iron-status biomarkers alone (trans-
ferrin, ferritin, and hemoglobin) or by inclusion of iron and sTfR
in the composite indexes transferrin index and TfR:F, re-
spectively, were statistically significant predictors of mortality.
Because of the nature of iron metabolism, depending on the
biomarker of interest, elevated iron status is defined by higher
(ie, plasma iron, transferrin index, and ferritin) or lower (ie,
sTfR, transferrin, and TfR:F) absolute concentrations. The re-
sults of this study indicate that increases in the concentration of
plasma iron, transferrin index, or ferritin (ie, toward an elevated
iron state) were associated with increased mortality [mortality
rate ratio (MRR) . 1.0], whereas increases in the concentration
of sTfR, transferrin, or TfR:F (ie, away from elevated iron state)
were protective (MRR , 1.0).
Because single unit changes in the concentration of a particular
biomarker are less straightforward to interpret in clinical practice,
a second analysis using biomarker concentrations classified
according to low, normal, or elevated iron status was conducted
(Table 4). In unadjusted models, both low and elevated iron
states were significantly associated with increased mortality
when compared with normal iron status. After adjustment, both
low and elevated iron status were associated with mortality, and
elevated iron status estimated by transferrin (adjusted MRR:
1.94; 95% CI: 1.42, 2.66; P , 0.001) and ferritin (adjusted
MRR: 1.55; 95% CI: 1.19, 2.02; P = 0.001) were the strongest
predictors of increased mortality. As expected, when classified
according to increasing severity of anemia, hemoglobin was
associated with increased mortality in both unadjusted and ad-
justed analyses.
Examination of the mortality rates in Table 5 showed an iron
status and mortality relation that was of similar direction be-
tween the HIV-1 and HIV-2 viruses, and the unadjusted MRR
indicated that, without exception, mortality rates were lower
with HIV-2 than with HIV-1. After adjustment for many factors
that could otherwise account for differences between viral types,
the adjusted models provide evidence of differential mortality
TABLE 2
Iron-related genes and mortality in unadjusted models (analyses A), adjusted models (analyses B), and an adjusted model (analyses C) with complete
genotype data from HP and SLC11A1 polymorphisms1
Analyses A2 Analyses B3,4 Analysis C4,5
Polymorphism and genotype Frequency (%) MRR (95% CI) P MRR (95% CI) P MRR (95% CI) P
Haptoglobin6
1–1 359 (33.2) 1 1 1
2–1 532 (49.2) 0.95 (0.79, 1.14) 0.583 0.79 (0.60, 1.03) 0.086 0.60 (0.37, 0.88) 0.012
2–2 191 (17.7) 0.93 (0.73, 1.19) 0.573 0.72 (0.50, 1.03) 0.075 1.32 (0.76, 2.30) 0.318
SLC11A1:SLC1
199/199 780 (70.1) 1 1 1
199/other 308 (27.7) 1.03 (0.85, 1.23) 0.789 1.31 (0.96, 1.75) 0.063 1.82 (1.07, 3.08) 0.026
other/other 24 (2.2) 0.61 (0.30, 1.22) 0.162 1.20 (0.56, 2.60) 0.640 10.00 (2.21, 45.36) 0.003
SLC11A1:SLC3
G/G 856 (83.4) 1 1 1
G/C 161 (15.7) 0.70 (0.55, 0.90) 0.004 0.59 (0.45, 0.85) 0.005 0.20 (0.09, 0.42) ,0.001
C/C 9 (0.9) 0.60 (0.19, 1.87) 0.380 0.60 (0.15, 2.45) 0.476 0.11 (0.01, 1.55) 0.101
SLC11A1:SLC6a
G/G 910 (87.8) 1 1 1
A/G 121 (11.7) 0.84 (0.64, 1.12) 0.240 1.06 (0.70, 1.62) 0.782 1.02 (0.48, 2.16) 0.958
A/A 5 (0.5) 0.27 (0.04, 1.92) 0.191 1.37 (0.19, 10.10) 0.757 11.03 (1.08, 112.43) 0.043
SLC11A1:SLC6b
ins/ins 710 (69.5) 1 1 1
ins/del 283 (27.7) 1.10 (0.91, 1.34) 0.300 1.29 (0.96, 1.71) 0.074 1.25 (0.73, 2.18) 0.414
del/del 28 (2.7) 0.81 (0.45, 1.48) 0.502 1.18 (0.54, 2.60) 0.675 0.71 (0.18, 2.73) 0.615
SLC11A1:CAAA
del/del 291 (29.7) 1 1 1
del/ins 453 (46.3) 1.16 (0.95, 1.43) 0.153 1.51 (1.10, 2.07) 0.011 2.08 (1.31, 3.31) 0.002
ins/ins 235 (24.0) 0.98 (0.77, 1.26) 0.885 1.06 (0.73, 1.55) 0.747 1.18 (0.65, 2.14) 0.580
1 SLC11A1 polymorphisms SLC1 = rs34448891, SLC3 = rs3731865, SLC6a = rs17235409, SLC6b = rs17235416, and CAAA = rs17229009. Mortality rate
ratios (MRRs) and 95% CIs were computed by using simple and multivariate Poisson regression analyses.
2 Missing genotype data permitted the following number of subjects to be analyzed: HP = 1082, SLC1 = 1112, SLC3 = 1026, SLC6a = 1036, SLC6b =
1021, and CAAA = 979.
3 Missing confounder data permitted 520–575 subjects to be analyzed.
4 Models were adjusted for sex, age, HIV type, absolute CD4 cell counts, BMI, a1-antichymotrypsin, hemoglobin, and ethnicity.
5 Model analysis includes the 304 subjects with complete cofactor and genotype data for both genes.
6 HP genotypes were classified into categories for statistical purposes: Hp 1–1 = Hp1F/1F, Hp1F/1S, Hp1S/1S; Hp 2–1 = Hp2FS/1F, Hp2FS/1S; and Hp 2–2 =
Hp2FS/2FS.
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between HIV-2 and HIV-1. However, with the exception of
normal iron status estimated by TfR:F, mortality differences
between viruses were statistically significant only in the pres-
ence of abnormal iron status (ie, lower than or higher than
normal iron status).
Gene-nutrient interaction and mortality
Predicted MRRs are shown in (Table 6), and demonstrate that
while increasing joint iron and gene risks are apparent, category-
specific conclusions are limited because of the restricted sub-
ject numbers with complete genetic and iron-status data. A
TABLE 3
Baseline iron status as a predictor of mortality analyzed by concentration1
Unadjusted Adjusted2
Iron-status biomarker MRR (95% CI) per unit change P MRR (95% CI) per unit change P
sTfR (nmol/L) 1.005 (1.002, 1.008) 0.002 0.998 (0.993, 1.004) 0.530
Iron (lmol/L) 0.942 (0.928, 0.955) ,0.001 1.003 (0.984, 1.023) 0.749
Transferrin (g/L) 0.220 (0.193, 0.250) ,0.001 0.600 (0.474, 0.760) ,0.001
TfR:F 0.337 (0.301, 0.378) ,0.001 0.701 (0.600, 0.819) ,0.001
Transferrin index (lmol/g) 1.025 (1.022, 1.028) ,0.001 1.033 (1.001, 1.055) 0.002
Ferritin (lg/L) 1.0015 (1.0014, 1.0016) ,0.001 1.0006 (1.0004, 1.0008) ,0.001
Hemoglobin (g/L)3 0.738 (0.711, 0.765) ,0.001 0.921 (0.878, 0.967) 0.001
1 Mortality rate ratios (MMRs) and 95% CIs were computed by using simple and multivariate Poisson regression
analyses. sTfR, soluble transferrin receptor; TfR:F, log(sTfR:ferritin).
2 Adjusted for sex, age, HIV type, absolute CD4 cell counts, BMI, a1-antichymotrypsin, and hemoglobin. Model
analysis included the 834–835 subjects with complete cofactor data.
3 Model analysis included the 1015 subjects with complete hemoglobin concentration data.
TABLE 4
Baseline iron status as a predictor of mortality analyzed by clinical classification1
Clinical classification
of iron status2
Frequency
(%)
Unadjusted Adjusted3
MRR (95% CI) P MRR (95% CI) P
sTfR
Low 443 (32.5) 1.42 (1.22, 1.67) ,0.001 0.85 (0.67, 1.06) 0.150
Normal 849 (62.4) 1 1
Elevated 69 (5.1) 1.19 (0.87, 1.64) 0.280 0.97 (0.62, 1.52) 0.894
Iron
Low 698 (51.4) 2.28 (1.96, 2.65) ,0.001 1.05 (0.84, 1.32) 0.676
Normal 642 (47.3) 1 1
Elevated 17 (1.3) 3.55 (2.03, 6.18) ,0.001 1.15 (0.36, 3.65) 0.819
Transferrin
Low 2 (0.1) — —
Normal 389 (28.6) 1 1
Elevated 968 (71.2) 5.32 (4.29, 6.60) ,0.001 1.94 (1.42, 2.66) ,0.001
TfR:F
Low 139 (10.2) 0.42 (0.30, 0.58) ,0.001 0.61 (0.40, 0.92) 0.020
Normal 900 (60.1) 1 1
Elevated 322 (23.7) 4.46 (3.82, 5.21) ,0.001 1.45 (1.13, 1.87) 0.004
Transferrin index
Low 564 (41.6) 1.27 (0.98, 1.64) 0.071 1.25 (0.87, 1.78) 0.227
Normal 160 (11.8) 1 1
Elevated 633 (46.6) 1.41 (1.10, 1.81) 0.007 1.44 (1.01, 2.04) 0.044
Ferritin
Low 129 (9.5) 0.54 (0.37, 0.80) 0.002 0.64 (0.39, 1.03) 0.064
Normal 574 (42.1) 1 1
Elevated 659 (48.4) 4.52 (3.84, 5.32) ,0.001 1.55 (1.19, 2.02) 0.001
Hemoglobin4
Severe anemia 201 (19.8) 4.68 (3.79, 5.77) ,0.001 1.49 (1.16, 1.91) 0.002
Anemia 288 (28.4) 2.52 (2.06, 3.08) ,0.001 1.27 (1.02, 1.58) 0.036
Normal 526 (51.8) 1 1
1 Mortality rate ratios (MRRs) and 95% CIs were computed by using simple and multivariate Poisson regression
analyses. —, insufficient no. of subjects; sTfR, soluble transferrin receptor; TfR:F, log(sTfR:ferritin).
2 For clinical classification limits, refer to Table 1.
3 Adjusted for sex, age, HIV type, absolute CD4 cell counts, BMI, a1-antichymotrypsin, and hemoglobin. Model
analysis included the 834–835 subjects with complete cofactor data.
4 Model analysis included the 1015 subjects with complete hemoglobin concentration data.
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comparison of the model without interaction with the model
with interaction showed good evidence of an interaction on the
multiplicative scale (likelihood-ratio test: P = 0.018).
DISCUSSION
This is the only reported study that has evaluated poly-
morphisms of 2 iron-related genes and the gene-nutrient in-
teraction as predictors of mortality in HIV infection to our
knowledge. We find that clinically abnormal iron status is an
important predictor of mortality, and, for the first time in HIVor
indeed any other infection or clinical condition, we observed that
SLC11A1 genotypes also predicted mortality. In this study, we
also report the presence of a novel gene-nutrient interaction
between the iron-related genetic and iron-status risks in asso-
ciation with mortality.
Similarly to others (1–3), we found an inverse association
between hemoglobin and mortality, which highlights the clinical
utility of this routinely measured marker. However, we also
showed that elevated iron status estimated from several different
biomarkers is a strong risk factor for mortality. Together, these
findings underscore that iron status at both ends of the continuum
exist in HIV infection and that both states are important predictors
of mortality.
Unique to this cohort was the ability to evaluate relations
between iron and mortality in the 2 different human immuno-
deficiency viruses. Current evidence indicates a longer survival
time with HIV-2 than with HIV-1 infection, but this advantage is
limited to persons without advanced immunosuppression (12).
The relation between iron status and mortality has not been
previously reported in the context of viral type. It is apparent that
among subjects with normal iron status, mortality does not
significantly differ between HIV-1 and HIV-2. However, among
subjects classified as having clinically abnormal iron status, HIV-
type becomes an important predictor of mortality. Under these
circumstances, HIV-2 has a more favorable mortality outcome
than does HIV-1, and this association persists even after the
control for degree of immunosuppression and clinical and de-
mographic cofactors.
The APR is associated with low and elevated iron status (4,
22); therefore, it could be argued that biomarkers of iron status
are proxies for clinical and subclinical infections. In this study,
infection status was assessed and controlled for in the analyses,
however, the possibility of residual confounding remains. Even if
the biomarkers were proxy indicators, the strong and consistent
TABLE 5
Mortality rate ratios (MRRs) of HIV-1 and HIV-2 subjects by iron status1
Clinical classification of
iron status2
MR/100 PY
(95% CI)
Unadjusted MRR
(95% CI)
Adjusted3 MRR
(95% CI)
HIV-1 HIV-2 HIV-2 vs HIV-1 P HIV-2 vs HIV-1 P
sTfR
Low (439) 42.7 (37.5, 50.9) 23.7 (19.2, 29.2) 0.54 (0.42, 0.70) ,0.001 0.54 (0.36, 0.77) 0.001
Normal (657) 28.1 (25.2, 31.4) 15.9 (13.1, 19.2) 0.57 (0.43, 0.75) ,0.001 0.76 (0.55, 1.05) 0.094
Elevated (69) 32.8 (22.9, 46.9) 17.9 (9.9, 32.4) 0.55 (0.27, 1.09) 0.087 —
Iron
Low (697) 46.9 (41.9, 52.6) 28.1 (23.2, 33.9) 0.60 (0.48, 0.75) ,0.001 0.66 (0.49, 0.90) 0.008
Normal (633) 21.6 (18.8, 24.8) 12.6 (10.3, 15.6) 0.59 (0.46, 0.75) ,0.001 0.71 (0.50, 1.02) 0.062
Elevated 22) 32.3 (16.1, 64.5) — — —
Transferrin
Low (5) 37.0 (9.2, 148.0) — — —
Normal (382) 9.0 (7.0, 11.7) 6.5 (4.7, 9.0) 0.72 (0.48, 1.10) 0.126 0.70 (0.39, 1.27) 0.243
Elevated (961) 47.6 (43.3, 52.2) 31.0 (26.6, 36.0) 0.65 (0.54, 0.78) ,0.001 0.72 (0.56, 0.92) 0.009
TfR:F
Low (137) 12.8 (8.9, 18.6) 4.8 (2.5, 9.3) 0.38 (0.18, 0.80) 0.011 0.27 (0.10, 0.78) 0.014
Normal (888) 24.5 (21.8, 27.6) 15.9 (13.4, 18.8) 0.65 (0.53, 0.80) ,0.001 0.69 (0.51, 0.92) 0.011
Elevated (319) 101.0 (87.7, 116.5) 75.1 (58.8, 95.9) 0.74 (0.56, 0.99) 0.040 0.80 (0.51, 1.25) 0.320
Transferrin index
Low (562) 32.7 (28.5, 37.7) 16.4 (13.0, 20.7) 0.50 (0.38, 0.66) ,0.001 0.57 (0.40, 0.83) 0.003
Normal (164) 24.5 (18.8, 32.0) 13.9 (9.1, 21.4) 0.57 (0.34, 0.94) 0.028 1.23 (0.57, 2.68) 0.598
Elevated (626) 33.5 (29.6, 37.9) 21.8 (18.1, 26.2) 0.65 (0.52, 0.81) ,0.001 0.70 (0.50, 0.98) 0.038
Ferritin
Low (126) 10.3 (6.7, 16.0) 5.1 (2.6, 9.7) 0.49 (0.22, 1.08) 0.076 0.25 (0.08, 0.84) 0.025
Normal (563) 15.8 (13.4, 18.7) 10.2 (8.0, 12.9) 0.64 (0.48, 0.86) 0.003 0.82 (0.55, 1.21) 0.317
Elevated (653) 70.3 (63.2, 78.1) 47.2 (39.7, 56.1) 0.67 (0.55, 0.82) ,0.001 0.65 (0.48, 0.88) 0.006
Hemoglobin
Severe anemia (537) 48.4 (42.6, 55.0) 22.6 (18.2, 28.0) 0.47 (0.36, 0.60) ,0.001 0.58 (0.42, 0.79) 0.001
Anemia (624) 39.1 (34.5, 44.3) 21.5 (17.6, 26.3) 0.55 (0.43, 0.70) ,0.001 0.57 (0.42, 0.76) ,0.001
Normal (855) 23.2 (20.6, 26.1) 14.1 (11.8, 16.9) 0.61 (0.49, 0.75) ,0.001 0.86 (0.66, 1.12) 0.259
1 MRRs and 95% CIs were computed by using simple and multivariate Poisson regression analyses. MR, mortality rate; PY, person-years; sTfR, soluble
transferrin receptor; TfR:F, log(sTfR:ferritin); 2, insufficient subjects available for analysis.
2 For clinical classification limits, see Table 1.
3 Adjusted for sex, age, absolute CD4 cell counts, BMI, a1-antichymotrypsin, and hemoglobin (if applicable).
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association with mortality remains an important clinical obser-
vation because extensive laboratory investigations during HIV
infection can be impractical in resource-limited settings. Even
regular monitoring of the established surrogate markers, CD4 cell
counts, and viral load remains economically prohibitive in some
resource-limited settings, prompting calls for alternative markers
to be developed (23).
The genetic findings we report provide additional support for
the need to fully understand iron metabolism and homeostasis in
HIV infection. In this study, the heterozygous HP genotype was
significantly protective, whereas in a study of European HIV-1
seropositive males, Hp 2–2 phenotypes were associated with
shorter survival (9). In healthy males, Hp 2–2 is associated with
greater iron status accumulation, estimated on the basis of
greater monocyte/macrophage L-ferritin concentrations; higher
serum iron, ferritin, and transferrin saturation; lower sTfR values
(24); and greater hemoglobin-iron driven oxidative stress (25);
however, these findings are not universal (26, 27). The survival
advantage that we observed could also be due to benefits con-
ferred by the heterozygous Hp genotype (28, 29) in regions with
higher generalized infectious burdens via mechanisms unrelated
to iron status.
For the first time, this study describes the relation between
SLC11A1 polymorphisms and mortality. We observed both
protective (SLC3:G/C) and hazardous genotypes (SLC1:199/
other, SLC1:other/other, SLC6a:A/A, and CAAA:del/ins) and
demonstrate the relevance of considering these associations in
the context of confounding factors. SLC11A1 genotypes may
influence mortality through differential susceptibility to in-
fection due to differences in the iron concentration at the level of
the macrophage. SLC11A1 and TB susceptibility has been
widely studied, and a meta-analysis of HIV-seronegative sub-
jects (11) reported the SLC1:other and SLC6a:A alleles were
associated with an increased odds of TB, whereas most of the
studies observed that the SLC3:C allele was protective. In the
present cohort, subjects with a diagnosis of TB (approximately
18% of the total cohort) had higher mortality than did those
without TB (30). Variants in the SLC11A1 gene may influence
the function of the SLC11A1 protein, although the exact mech-
anism remains speculative. SLC11A1 is known to localize to the
late endosomal membrane and may affect the early innate im-
mune response to infection through the regulation of iron levels
(31, 32). Iron is essential to pathogens, but is also required by
the host to generate reactive oxygen/nitrogen intermediates and
as a cofactor for superoxide dismutase and catalase that are used
to neutralize the cytotoxic effects of the host macrophage oxi-
dative burst (33).
In many instances, gene-environment interactions are thought
to be the most important factor in disease onset (34), yet they are
rarely investigated. Reports of gene-environment interactions are
even rarer in large, longitudinal studies such as the present cohort.
Until gene-nutrient interactions are examined and reported, ad-
vancing knowledge at the gene-nutrient interface remains re-
stricted. Detecting statistical interaction between iron status and
iron-related genes is a novel finding, and, in this study, it appears
that mortality is affected by certain genetic backgrounds in the
presence of nutritional factors. Limited subject numbers resulted
in wide CIs at the category-specific level, and because this
analysis was not adjusted for potential confounding variables,
interpretations must remain preliminary. Supplementary evidence
TABLE 6
Predicted mortality rate ratios (MRRs) of the combined gene-nutrient risk in HIV infection1
Genetic risk2
Low Medium High
Model without interaction
represented by
MRRg · MRRe =
MRR (95% CI)3
Iron-risk4
Low Reference group: 1 · 1 = 1 1.13 · 1 = 1.13 (0.80, 1.59) 1.28 · 1 = 1.28 (0.91, 1.79)
Medium 1 · 3.24 = 3.24 (2.47, 4.26) 1.13 · 3.24 = 3.66 (1.99, 6.79) 1.28 · 3.24 = 7.20 (2.25, 7.62)
High 1 · 7.57 = 7.57 (5.37, 10.68) 1.13 · 7.57 = 8.55 (4.31, 17.02) 1.28 · 7.57 = 9.69 (4.88, 19.09)
Model with interaction
represented by
MRRg · MRRe ·
MRRge =
MRR (95% CI)3
Iron-risk4
Low Reference group: 1 · 1 · 1 = 1 1.61 · 1 · 1 = 1.61 (0.83, 3.11) 1.53 · 1 ·1 = 1.53 (0.79, 2.94)
Medium 1 · 3.98 · 1 = 3.98 (1.99, 7.96) 1.61 · 3.98 · 0.60 = 3.84 (0.70, 15.53) 1.53 · 3.98 · 1.00 = 6.09 (0.71, 52.76)
High 1 · 13.78 · 1 = 13.78 (5.95, 31.89) 1.61 · 13.78 · 0.70 = 15.53 (1.27, 188.98) 1.53 · 13.78 · 0.41 = 8.64 (0.72, 103.31)
1 Predicted MRRs and 95% CIs were calculated by using the observed MRRs and SEs computed by using simple Poisson regression analyses. The
likelihood-ratio test was used to assess evidence of interaction on a multiplicative scale, and the calculated P value = 0.018. MRRge, predicted MRR of the
joint effect of genotypes and iron status; MRRg, predicted MRR of the main effect of genotypes; MRRe, predicted MRR of the main effect of iron status.
2 High-risk genotypes were coded as Hp:1–1, HP 2–2; SLC1:199/other, other/other; SLC3:G/G; SLC6a:A/A; SLC6b:ins/del; CAAA:del/ins, ins/ins = 1;
otherwise = 0. Individual genotype risks were added, giving an overall genetic-risk score of low = 0–1, medium = 2–3, and high = 4.
3 Model analysis included the 586 subjects with complete biomarker and genotype data for all polymorphisms from both genes.
4 According to the cutoffs established from the literature in Table 1, elevated iron status was coded as 1 and otherwise as 0. Individual iron risks were
added, giving an overall iron-risk score of low = 0–1, medium = 2–3, and high = 4.
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from additional studies is needed to confirm support for the
biologically plausible hypothesis of a gene-nutrient interaction
and to more precisely indicate the nature of the effects at the
category-specific level. Ultimately, our findings, combined with
those of future studies, may contribute to a pooled meta-analysis
that is designed to provide such insight.
Limitations associated with this study include the potential for
some bias due to the unequal distribution in losses to follow-up.
Direct comparisons are difficult because reporting the nature and
magnitude of loss-to-follow-up is limited in studies that have been
conducted in similar settings. We considered potential discrep-
ancies in genotype calls unlikely to strongly bias findings because
all polymorphisms were in HWE, with the exception of CAAA.
Overall, our observations have clinical implications because
programmatic as well as less-formalized distribution of iron
supplements occurs in resource-limited regions. At this time,
however, there is growing concern over the conflicting and in-
sufficient evidence that surrounds the safety or efficacy of iron
supplementation during infection or in regions with high in-
fectious burdens (5, 6, 35–40). Some studies have reported that
iron supplementation or elevated iron status is not associated with
negative outcomes in HIV infection (37, 39, 41), whereas our
evidence (5) and that of others (6, 42) suggests the opposite. All-
cause mortality is a definitive endpoint, and perhaps the HIV viral
load (39, 41) insufficiently assesses the full effect of abnormal
iron status if the responsible mechanisms are unrelated to viral
load, such as increased susceptibility to opportunistic infections.
Another important difference that may partly explain these
discrepancies is that we observed effects for both sexes at all
stages of infection, whereas other studies were restricted to
pregnant women (37) or female hepatitis C–positive injection
drug users (39) or included very small numbers of male subjects
(41) followed over short time periods.
This study showed that iron-related genes, clinically abnormal
iron status, and a gene-nutrient interaction predict mortality
among men and women with HIV-1 and HIV-2 infection in The
Gambia. Additional research is needed to elucidate the re-
sponsible mechanisms. Defining the best practice for the clinical
management of iron status and anemia during HIV infection is
complex and incomplete.
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